Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Maybe my 50 cent order will get placed.
Why take a drug to hack your liver when Vascepa gets to root cause? Diabetes and cataracts?…yea!
“whereas excess cataracts may be related to rosuvastatin's more potent LDL cholesterol lowering -- namely the prevention of epithelial cell development within the crystalline lens.
Importantly, greater LDL cholesterol lowering with rosuvastatin did not translate to fewer clinical events. Recent evidence suggests that in people already on statin therapy, it is inflammation, not cholesterol per se, that is the bigger contributor to residual cardiovascular risk.”
https://www.medpagetoday.com/cardiology/prevention/106912
What is your source for these numbers?
I’ve got an order in at 50 cents.
Not perfect, but something.
https://www.cnbc.com/2023/10/13/short-sellers-will-have-to-report-more-data-under-new-us-sec-rules.html#:~:text=The%20rules%2C%20first%20proposed%20in,regulatory%20body%20that%20polices%20brokers.
The two dirtbags who voted against.
“The SEC’s two Republican members voted against the rule. Commissioners Hester Peirce and Mark Uyeda questioned the rulemaking process, including the short initial consultation period, and the speed of the implementation timetable.”
That’s great! Makes it better for the next patient too.
Cardiology: where science goes to die.
Perhaps ask your cardiologist for a referral to a cardiologist who practices evidence based medicine.
That’s what it looks like. FFS thinks it may be a short cover/squeeze signal. But… this is Amarin so normal market dynamics probably don’t apply. Anyway, 10+% drop on Monday and then a short free day on Tuesday?
Hope it proves out this time.
What is SSR for Stocks?
The short-sale rule (SSR) is a restriction on short selling that is triggered if the price of a stock drops by more than 10% from the previous close. It makes shorting that stock effectively impossible until the end of the next market day.
Mentioned on Stocktwits today that Amarin is on an SSR list and can’t be shorted today. So do they double down on Monday?
Wonder if Ozempic cures Alzheimer’s too?
How do I reconcile 4.7M volume today with 1.266M in this report? How do you conclude it is GS?
At least we aren’t SAVA.
Could you please post substantiation of your claims?
That’s a risk but my potassium levels have stayed normal.
I’ve been watching the Ozempic craze with a jaundiced eye. Of course it would have been a home run if a diabetes drug also helped CKD. Meanwhile, intestinal paralysis…. What else could possibly go wrong!
Here’s a drug that actually might help diabetic CKD.
https://www.bristol.ac.uk/news/2023/february/diabetic-kidney-disease.html#:~:text=Their%20results%20showed%20spironolactone%20reduces,the%20kidney%2C%20preventing%20disease%20progression.
One of the BP meds I take is Spironolactone.
My 78 cent order didn’t get taken out today. Feels like the MM’s are tickling the tail of the dragon.
Anyone else have a buy order at $0.78?
Interesting. I’ve been on Vascepa about 5 years. My insurance company (Aetna Medicare Advantage) doesn’t cover generic (at least this year)
I can’t take a statin, but in any event, my LDL was less than 100 last year for the first time ever.
I’m wondering if you (or anyone else here) has noticed BP improvement on Vascepa? I’ve been on 3 drugs the last 3 years or so and until recently still borderline. Moreover, the side effects have been unwelcome, especially Carvedilol. A few months ago I began seeing consistently low numbers (less than 100) and having some light headedness issues. My doc agreed to cut the dose of Carvedilol in half. A month later, BP still low. She said cut Carvedilol in half again. Still. Ok after a couple weeks. Might be able to get off it entirely. Carvedilol is actually a heart failure drug but often used for hypertension. It reduces adrenaline output for one thing and really messes with your energy level. I’ve been feeling much better as dose has gone down.
Regarding HDL, avoid going too high.
https://www.nbcnews.com/health/heart-health/good-hdl-cholesterol-dementia-risk-rcna118772
Typo most likely. BRAVE-EPA
You need to have your cliche-o-matic software updated:
“Cash” is king. Not price.
So….
FDA concludes (finally) that this crap (non-prescription) doesn’t work to relieve your cold symptoms. You know, colds that resolve anyway, regardless of what you do.
Meanwhile, proven worthless prescription drug Lovaza, prescribed to protect you from actual death from heart disease continues unimpeded!
https://www.cnn.com/2023/09/15/health/decongestants-alternatives-wellness/index.html
Please discuss Sarissa purchase of 4M shares in August. Show your work.
Thanks for posting. Quite a change in thinking regarding AA/EPA ratio from when you talked to him.
Agree. Prior studies, while not conclusive, could be seen as hypothesis generating and likely informed the design of her trial. Moreover, Denner has the resources to have tasked his technical team to fully research IPE before investing in Amarin.
The 6 publications you shared (I had most of them bookmarked) going back to 2008 certainly give hope that BRAVE may demonstrate encouraging results.
Here are others you may know of or have shared before.
https://link.springer.com/content/pdf/10.1007/s00401-020-02215-w.pdf
https://www.j-alz.com/content/can-omega-3-help-prevent-alzheimers-disease
https://static1.squarespace.com/static/5c17c5504eddec8821773e82/t/5d03d5f2bf259d00016373ac/1560532468308/Song+et+al+2014.pdf
https://content.iospress.com/download/journal-of-alzheimers-disease/jad130131?id=journal-of-alzheimers-disease%2Fjad130131
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537710/pdf/BMRI2015-172801.pdf
https://onlinelibrary.wiley.com/doi/full/10.1111/joim.12166
https://academic.oup.com/biomedgerontology/article/72/6/796/2630058
https://www.science.org/content/article/potential-fabrication-research-images-threatens-key-theory-alzheimers-disease
https://www.uspharmacist.com/article/some-statins-appear-to-increase-dementia-in-patients-with-mild-cognitive-issues
“…. to assess whether IPE improves cognitive performance on the ADCS-PACC battery compared to placebo.”
My understanding is they are comparing IPE results vs. the placebo, not vs. the heathy baseline of patients at the start of the trial. Improvement of cognitive performance of healthy patients would be remarkable , unexpected, and I’m all for it! Sadly, that doesn’t seem to be the case for me although I’m ever hopeful.
Your point eludes me.
BRAVE is testing for cognitive function in the context of an Alzheimer’s trial, not mushrooms, etc.
If cognitive function decline occurs consistently with change in biomarkers, then that suggests onset of dementia. These are patients with known risk factors for Alzheimer’s.
Please substantiate your claim that BRAVE is exclusively a biomarker study when cognitive function test is explicitly stated in the trial plan.
Indeed. I do hope they report top-line results quickly.
Don’t disagree, but if there is more cognitive decline in the placebo group than the Vascepa group and it tracks the biomarkers, conclusions will be drawn.
I believe decline in healthy people is how AD manifests itself. My sister has AD. She was healthy. Then she declined. Why wouldn’t there be a decline in heretofore healthy participants. The trial cohort was chosen because they were seen to be in an at-risk population.
So, doing an Occam's Razor analysis, my judgment is if there’s a decline, it’s due to the disease.
I don’t understand. If there is decline, would it not have a cause? If there is no disease at trial start, wouldn’t decline mean disease onset? Why measure cognitive change? If there is decline and it is not due to disease progression, then what is it?
“The proposed study aims to: 1) investigate the effects of 18 months of IPE vs. placebo on regional cerebral blood flow as measured by arterial spin-labeling MRI; 2) determine the impact of 18 months of IPE vs. placebo on CSF biomarkers of AD pathology; and 3) evaluate the effects of 18 months of IPE vs. placebo on cognitive performance.”
#3 is about disease progression.
“The relationship between higher concentrations of EPA and a decreased risk for incident all-cause dementia was significant among APOE e4 noncarriers (Model 2: HR = 0.76, 95% CI 0.61, 0.94) but not among APOE e4 carriers (Table S4). Furthermore, higher concentrations and higher proportions of EPA were associated with a decreased risk for incident AD dementia among APOE e4 noncarriers (concentrations, Model 2: HR = 0.66, 95% CI 0.51, 0.84; proportions, Model 2: HR = 0.80, 95% CI 0.65, 0.99) but not among APOE e4 carriers”
Findings from this study may be of some concern because I believe BRAVE includes APOE e4 carriers.
Denner either took advantage of the situation or manipulated the situation in order to buy 4M shares at a low cost.
Now Tat’s feelings are hurt: “He wants to keep massaging the SP to his benefit. He's straight up manipulating this.”
Nothing has changed and I won’t be surprised if SP continues on this path with perhaps another 13D in a few weeks.
Pharmacydude,
Thanks, saw the ST post but many here probably didn’t. It’s good to see Dr Bhatt defending his work. Hope Amarin makes this and other research available to us.
The health care industry is not incentivized for prevention, at least where heart disease is concerned. My wife had a coronary artery calcium scan a few months ago (CAC scan). Medicare Advantage plan would not pay. Inexpensive, $200, but still.
This so-called research article is an embarrassment. I wonder if any of the authors other than Ridker even reviewed it. Bhatt must have been horrified.
I think the most egregious failing, something a college freshman would get a failing grade for, was not addressing other factors besides mineral oil that could have accounted for these biomarkers to increase. Like 2 years age maybe.
Ridker had a conclusion in mind and then wrote a paper to defend it.
Looked to me like Pdude was referring to last weekend. Where’s the 2023 stuff. Not to put too fine a point on it, but Amarin’s website is a piece of shit.
2021?